Hydrochloric Acid → 4-(4-Benzyloxy-phenyl)-3-butyl-6-(3-piperidin-1-yl-propoxy)-pyridazine dihydrochloride
反応式
[CH2:1]([O:8][C:9]1[CH:14]=[CH:13][C:12]([C:15]2[CH:20]=[C:19]([O:21][CH2:22][CH2:23][CH2:24][N:25]3[CH2:30][CH2:29][CH2:28][CH2:27][CH2:26]3)[N:18]=[N:17][C:16]=2[CH2:31][CH2:32][CH2:33][CH3:34])=[CH:11][CH:10]=1)[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[ClH:35]>O1CCOCC1>[ClH:35].[ClH:35].[CH2:1]([O:8][C:9]1[CH:14]=[CH:13][C:12]([C:15]2[CH:20]=[C:19]([O:21][CH2:22][CH2:23][CH2:24][N:25]3[CH2:30][CH2:29][CH2:28][CH2:27][CH2:26]3)[N:18]=[N:17][C:16]=2[CH2:31][CH2:32][CH2:33][CH3:34])=[CH:11][CH:10]=1)[C:2]1[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=1参加物
4
実験手順
4-(4-Benzyloxy-phenyl)-3-butyl-6-(3-piperidin-1-yl-propoxy)-pyridazine was dissolved in 4.0 M HCl in dioxane and evaporated the solvent. The resultant salt was washed with ether and dried to provide the title compound (20 mg). LCMS: m/z 461 [M+1]. 1H NMR (400 MHz, CD3OD) 7.35 (2H, d), 7.21-7.25 (5H, m), 7.03 (2H, d), 6.91 (1H, s), 5.06 (2H, s), 4.48 (2H, t), 3.48 (2H, d), 2.80-2.91 (4H, m), 2.23 (2H, s), 1.73-1.1.87 (6H, m), 1.36-1.41 (3H, m), 1.09-1.14 (3H, m), 0.68 (3H, t).